- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02648633
Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma
A Pilot Study to Evaluate the Feasibility of the Combined Use of Stereotactic Radiosurgery With Nivolumab and Concurrent Valproate in Patients With Recurrent Glioblastoma
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Immune checkpoint inhibitors have the potential to treat a wide range of diverse cancers. Of particular interest to researchers is the PD-1 receptor-ligand interaction, a major pathway that many cancers hijack in order to suppress immune control. Anti-PD-1 antibodies such as nivolumab show a strong potential to treat many types of cancers including glioblastoma, the most common and most lethal brain cancer.
This study will examine a means of further focusing immune response on glioblastoma by combining stereotactic "gamma knife" radiosurgery with nivolumab. The rationale behind this intervention is that the radiation therapy will enhance immune response rate by providing additional tumor antigens from dying cells. Additionally, a study from investigators at Johns Hopkins indicates that histone deacetylase (HDAC) inhibitors may boost the anti-cancer efficacy of PD-1 antibodies like nivolumab. Valproate, a class I HDAC inhibitor, will be used concurrently with nivolumab with the goal of enhancing the effects of both the nivolumab and the radiotherapy.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22908
- University of Virginia
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Confirmed malignant, recurrent glioblastoma or gliosarcoma
- Subject must have adequate organ function
- Subject must still be able to care for most of his or her personal needs
Exclusion Criteria:
- Subject is pregnant
- Subject has extracranial metastatic or leptomeningeal disease
- Subject has an additional malignancy that is progressing or requires active treatment, exceptions being basal cell and squamous cell carcinomas of the skin, indolent prostate cancer, chronic lymphocytic leukemia, or in situ cervical cancer
- Subject has received chemotherapy, biological therapy, or had surgery 4 weeks prior to beginning the study
- Subject has had radiation therapy within 10 weeks prior to entering beginning the study
- Subject has had prior therapy with bevacizumab
- Subject has had previous treatment with carmustine wafer except when administered as first-line treatment no less than six months prior to beginning the study
- Subject requires escalating supraphysiologic doses of corticosteroids greater than 2 mg of dexamethasone or an equivalent
- Active autoimmune disease requiring systemic treatment within the past 3 months or any syndrome that requires immunosuppressive agents
- Interstitial lung disease or active, non-infectious pneumonitis
- Evidence of greater than Grade 1 CNS hemorrhage or greater than Grade 3 venous thromboembolism
- History of uncontrolled cardiac disease
- Subject unable or unwilling to have a head contrast enhanced MRI
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Nivolumab & Valproate Following G.K.
Subjects will begin a valproate regimen prior to undergoing stereotactic radiosurgery (gamma knife) on a single lesion.
Following the surgery, subjects will receive nivolumab every 2 weeks and daily valproate.
|
Subjects will receive a single large dose of radiation to one or more lesions.
Andre navne:
3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
Andre navne:
Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab.
Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Feasibility based on number of subjects who complete 4 doses of nivolumab
Tidsramme: At 3 months following radiosurgery
|
Feasibility of the radiosurgery and drug combination will be determined based on the number of subjects who complete at least 4 doses of nivolumab.
|
At 3 months following radiosurgery
|
Incidence of adverse events
Tidsramme: From the beginning of treatment until no sooner than 30 days following the last study treatment
|
Safety will be assessed by imaging of necrosis, incidence and severity of adverse events, changes in laboratory findings, physical examinations, vital signs, and the number of discontinuations due to adverse events.
|
From the beginning of treatment until no sooner than 30 days following the last study treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Clinical Response Rate
Tidsramme: From the beginning of treatment until documented disease progression or date of death, assessed up to 48 months.
|
Response to therapy will be evaluated by means of RANO criteria.
|
From the beginning of treatment until documented disease progression or date of death, assessed up to 48 months.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Incidence of Pseudoprogressions
Tidsramme: From the beginning of treatment until documented disease progression or date of death, assessed up to 48 months.
|
Pseudoprogression, the transient increase in apparent tumor size, will be documented.
|
From the beginning of treatment until documented disease progression or date of death, assessed up to 48 months.
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Benjamin Purow, MD, University of Virginia
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter histologisk type
- Neoplasmer
- Neoplasmer, kirtel og epitel
- Astrocytom
- Gliom
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Glioblastom
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Depressive midler til centralnervesystemet
- Enzymhæmmere
- Antineoplastiske midler
- Antineoplastiske midler, immunologiske
- Beroligende midler
- Psykotropiske stoffer
- GABA agenter
- Antikonvulsiva
- Antimaniske midler
- Immune Checkpoint-hæmmere
- Nivolumab
- Valproinsyre
Andre undersøgelses-id-numre
- 18574
- CA209-378 (Anden identifikator: University of Virginia)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Glioblastom
-
Milton S. Hershey Medical CenterRekrutteringGlioblastom | Glioblastoma Multiforme | Glioblastoma Multiforme, voksen | Glioblastoma Multiforme i hjernenForenede Stater
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RekrutteringGlioblastom | Glioblastoma Multiforme | Glioblastoma Multiforme, voksen | Glioblastoma Multiforme i hjernenForenede Stater
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... og andre samarbejdspartnereRekrutteringGlioblastom | Glioblastoma Multiforme | Glioblastom, IDH-vildtype | Glioblastoma Multiforme, voksen | Glioblastoma Multiforme i hjernenForenede Stater, Belgien, Schweiz, Tyskland, Holland
-
University of UtahTrukket tilbageGlioblastoma Multiforme (GBM)Forenede Stater
-
TVAX BiomedicalFDA Office of Orphan Products DevelopmentRekrutteringGlioblastoma Multiforme i hjernenForenede Stater
-
Shenzhen Geno-Immune Medical InstituteTilmelding efter invitationGlioblastoma Multiforme | Glioblastoma Multiforme i hjernenKina
-
University of Roma La SapienzaAfsluttetGlioblastoma Multiforme i hjernen
-
Imperial College LondonRekrutteringGlioblastoma Multiforme i hjernenDet Forenede Kongerige
-
Clinique Neuro-OutaouaisAfsluttetGlioblastoma Multiforme i hjernenCanada
-
Sunnybrook Health Sciences CentreRekrutteringGlioblastoma Multiforme, voksenCanada
Kliniske forsøg med Stereotactic Radiosurgery
-
CyberKnife Centers of San DiegoUkendt
-
National Taiwan University HospitalRekrutteringSekundær malign neoplasma i rygsøjlenTaiwan
-
CyberKnife Centers of San DiegoUkendtTilbagevendende prostatakræftForenede Stater
-
Swedish Medical CenterAktiv, ikke rekrutterende
-
Yale UniversityAfsluttetMelanom | Sarkom | Nyrecellekarcinom | Brystkræft | Kolorektal cancer | Lungekræft | Hjernemetastaser | Gastrointestinale kræftForenede Stater
-
University of California, San FranciscoAfsluttet
-
University of DundeeAfsluttetRektal neoplasmaDet Forenede Kongerige
-
Assistance Publique Hopitaux De MarseilleAfsluttet
-
Northwell HealthAfsluttetSpinale metastaserForenede Stater
-
Beth Israel Deaconess Medical CenterAfsluttet